By Denny Jacob
Shares of Esperion Therapeutics jumped 11% in premarket trading after fourth-quarter revenue more than doubled from the prior-year period.
Shares were trading around $1.76. The stock is down 34% over the last year.
The pharmaceutical company recorded revenue of $69.1 million, compared with $32.3 million a year earlier. Analysts polled by FactSet had expected $61.6 million.
"We expect to drive further revenue growth and reach operating profitability through durable growth of our bempedoic acid products in the U.S. and Europe, and through global expansion," said Chief Executive Sheldon Koenig.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 04, 2025 06:26 ET (11:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。